同和药业：公司目前在创新药领域暂无相关布局

Group 1 - The company has a total of 17 new products and over 30 research reserve varieties, with several global patent expirations scheduled between 2028 and 2033 [1] - Some products, such as Vabigatran, Rosuvastatin, and others, are already in the registration submission process, indicating ongoing development efforts [1] - The company plans to maintain multiple new product launches each year, creating a product lineup consisting of mature products, research (registration) products, and reserve products [1] Group 2 - Currently, there is no relevant layout in the innovative drug sector, indicating a focus on other areas [1] - The company's associate, Boya Biotech, primarily engages in the research and production of high-difficulty specialty formulations, which have high industry entry barriers [1] - Future business synergies are expected between the company and Boya Biotech, enhancing overall operational capabilities [1]